Aliases & Classifications for Prostatitis

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to atrophy of prostate and hepatitis, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Acetaminophen and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cardiovascular system

Wikipedia : 71 Prostatitis (less commonly prostatosis) is inflammation of the prostate gland. Prostatitis is classified... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 830)
id Related Disease Score Top Affiliating Genes
1 atrophy of prostate 32.1 CXCL8 IL10 IL1B IL6 TNF
2 hepatitis 29.7 IL10 IL6 TNF
3 papillary adenocarcinoma 29.7 IL10 TGFB1
4 pulmonary tuberculosis 29.4 CXCL8 IL10 IL6 TNF
5 meningitis 29.1 CXCL8 IL6 TNF
6 neuropathy 29.0 CXCL8 IL1B IL6 TNF
7 tuberculosis 28.9 IL10 IL1B IL6 TNF
8 nasopharyngitis 28.9 CXCL8 IL1B IL6 TNF
9 pyelonephritis 28.9 CXCL8 IL10 IL1B TNF
10 measles 28.7 IL1B IL6 TNF
11 choroiditis 28.7 CXCL8 IL10 IL1B IL6 TNF
12 osteonecrosis 28.6 CXCL8 IL1B IL6 TGFB1 TNF
13 myocardial infarction 28.6 IL10 IL1B IL6 PDE5A TGFB1 TNF
14 alcoholic hepatitis 28.6 CXCL8 IL10 IL6 TNF
15 colon adenocarcinoma 28.5 CXCL8 IL10 IL1B IL6 TNF
16 pyoderma gangrenosum 28.5 CXCL8 IL1B IL6 TNF
17 exophthalmos 28.3 CXCL8 IL10 IL1B IL6 TNF
18 rheumatoid arthritis 27.9 CXCL8 IL10 IL1B IL6 TGFB1 TNF
19 prostate cancer 12.9
20 prostate disease 12.3
21 prostate cancer 1 12.2
22 prostate adenocarcinoma 12.1
23 prostate stromal sarcoma 12.1
24 prostate rhabdomyosarcoma 12.1
25 prostate cancer, hereditary, 13 12.1
26 prostate cancer, hereditary, 2 12.1
27 prostate sarcoma 12.1
28 prostate leiomyosarcoma 12.1
29 prostate cancer, hereditary, 12 12.1
30 prostate cancer, hereditary, 11 12.1
31 prostate angiosarcoma 12.0
32 prostate embryonal rhabdomyosarcoma 12.0
33 prostate calculus 12.0
34 prostatic adenoma 12.0
35 prostatic hypertrophy 11.9
36 adenosquamous prostate carcinoma 11.9
37 prostate small cell carcinoma 11.9
38 prostate lymphoma 11.9
39 prostatic cyst 11.8
40 prostate carcinoma in situ 11.8
41 nodular prostate 11.8
42 prostate transitional cell carcinoma 11.8
43 prostate leiomyoma 11.8
44 prostatic acinar adenocarcinoma 11.8
45 prostatic malacoplakia associated with prostatic abscess 11.8
46 benign prostate phyllodes tumor 11.8
47 prostate cancer susceptibility 11.8
48 prostate signet ring cell adenocarcinoma 11.7
49 prostate adenoid cystic carcinoma 11.7
50 prostate squamous cell carcinoma 11.7

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Chronic Myocardial Ischemia Epididymo-Orchitis
Ischemic Heart Disease Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 IL1B TGFB1 TNF ADRA1A CXCL8 IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 IL1B TGFB1 TNF ADRA1A CXCL8 IL10

MGI Mouse Phenotypes related to Prostatitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ADRA1A IL10 IL1B IL6 PROS1 TGFB1
2 endocrine/exocrine gland MP:0005379 9.91 IL10 IL6 MSMB NKX3-1 TGFB1 TNF
3 digestive/alimentary MP:0005381 9.88 IL10 IL6 NKX3-1 TGFB1 TNF VDR
4 integument MP:0010771 9.87 IL10 IL1B IL6 PROS1 TGFB1 TNF
5 muscle MP:0005369 9.8 ADRA1A IL10 IL6 PROS1 TGFB1 TNF
6 neoplasm MP:0002006 9.7 TNF IL10 IL1B IL6 MSMB NKX3-1
7 reproductive system MP:0005389 9.5 IL10 IL6 MSMB NKX3-1 TGFB1 TNF
8 skeleton MP:0005390 9.17 IL10 IL1B IL6 NKX3-1 TGFB1 TNF

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Cycloserine Approved Phase 4,Phase 3 68-41-7 401 6234
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
4
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
5
Cefoxitin Approved Phase 4 35607-66-0 441199
6
Cilastatin Approved Phase 4 82009-34-5 5280454 6435415
7
Imipenem Approved Phase 4 74431-23-5 104838
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone Approved, Investigational Phase 4 58-22-0 6013
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11 Cholinergic Agents Phase 4,Phase 3,Phase 2
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
14 Analgesics Phase 4,Phase 3,Phase 2
15 Anti-Anxiety Agents Phase 4,Phase 3
16 Anticonvulsants Phase 4,Phase 3
17 calcium channel blockers Phase 4,Phase 3
18 Calcium, Dietary Phase 4,Phase 3
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
20 Psychotropic Drugs Phase 4,Phase 3
21 Tranquilizing Agents Phase 4,Phase 3
22 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
23 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antitubercular Agents Phase 4,Phase 3
26 Fluoroquinolones Phase 4,Phase 3
27 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3
28 Permixon Phase 4,Phase 3
29 Prulifloxacin Phase 4
30 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
31 Antimetabolites Phase 4,Phase 3
32 Renal Agents Phase 4,Phase 3
33 abobotulinumtoxinA Phase 4,Phase 3,Phase 2
34 Botulinum Toxins Phase 4,Phase 3,Phase 2
35 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2
36 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
37 Neuromuscular Agents Phase 4,Phase 3,Phase 2
38 onabotulinumtoxinA Phase 4,Phase 3,Phase 2
39 Androgens Phase 4,Phase 3,Early Phase 1
40 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
41 Hormones Phase 4,Phase 3,Early Phase 1
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1
43 HIV Protease Inhibitors Phase 4
44
protease inhibitors Phase 4
45 Anabolic Agents Phase 4
46 Antineoplastic Agents, Hormonal Phase 4
47 Pharmaceutical Solutions Phase 4,Phase 3
48 Testosterone 17 beta-cypionate Phase 4
49
Testosterone enanthate Phase 4 315-37-7 9416
50 Testosterone undecanoate Phase 4

Interventional clinical trials:

(show top 50) (show all 64)
id Name Status NCT ID Phase
1 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4
2 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4
3 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
4 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4
5 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Recruiting NCT02474706 Phase 4
6 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Active, not recruiting NCT02366975 Phase 4
7 Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
8 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4
9 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4
10 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4
11 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3
12 Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis Completed NCT00260637 Phase 2, Phase 3
13 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3
14 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis Completed NCT00402688 Phase 3
15 A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis Completed NCT00236808 Phase 3
16 Levofloxacin, Chronic Bacterial Prostatitis Completed NCT00277511 Phase 3
17 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00103402 Phase 3
18 Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) Completed NCT00169585 Phase 3
19 Complementary and Alternative Medicine for Urological Symptoms(CAMUS) Completed NCT00603304 Phase 3
20 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3
21 Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Not yet recruiting NCT02975570 Phase 3
22 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3
23 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3
24 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
25 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed NCT00740779 Phase 2
26 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2
27 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT00529386 Phase 2
28 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Completed NCT00826514 Phase 2
29 A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT01391338 Phase 2
30 An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland Completed NCT00236990 Phase 2
31 A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Completed NCT00362752 Phase 2
32 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2
33 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2
34 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
35 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2
36 Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis Unknown status NCT00913315
37 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
38 Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00499317
39 Non Interventional Study of Levofloxacin in Chronic Prostatitis Completed NCT02711943
40 Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome Completed NCT00922012
41 Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis Completed NCT01098279
42 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
43 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Completed NCT01826617
44 Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury Completed NCT01601041
45 Diagnostic Challenges in IC (and Male CPPS) Completed NCT00672087
46 2013 Annual National Digital Rectal Exam (DRE) Day Study Completed NCT01886547
47 Linkage Analysis in Interstitial Cystitis Completed NCT00675298
48 Observational Study of Control Participants for the MAPP Research Network Completed NCT01098292
49 Physical Therapy Trial for Pelvic Pain Completed NCT00434343
50 Sono-Electro-Magnetic Therapy for Refractory Chronic Pelvic Pain Syndrome Completed NCT00710073

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

39
Prostate, Bone, Breast, Endothelial, Lymph Node, Testes, Lung

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 21365)
id Title Authors Year
1
Signaling networks in TMPRSS2-ERG positive prostate cancers: Do we need a Pied Piper or sharpshooter to deal with "at large" fused oncoprotein. ( 28364793 )
2017
2
Prostatic abscess in a patient with chronic granulomatous disease: a multi-disciplinary intervention. ( 28218357 )
2017
3
Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. ( 28004109 )
2017
4
Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy. ( 27470607 )
2017
5
Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. ( 28086825 )
2017
6
Repeatability of [(68)Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. ( 28534214 )
2017
7
miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression. ( 27878260 )
2017
8
Atorvastatin prolongs the lifespan of radiationa89induced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect. ( 28260074 )
2017
9
Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection. ( 28089303 )
2017
10
Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. ( 28089387 )
2017
11
TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells. ( 28028835 )
2017
12
Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer. ( 28068638 )
2017
13
miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. ( 28122308 )
2017
14
Extra-Gastrointestinal Stromal Tumor of Prostate. ( 28418346 )
2017
15
Downregulation of Rab23 in Prostate Cancer Inhibits Tumor Growth In Vitro and In Vivo. ( 28277196 )
2017
16
High-Level I^-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. ( 28146062 )
2017
17
MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells. ( 28345464 )
2017
18
Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. ( 28532278 )
2017
19
Editorial Comment to Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology. ( 28087898 )
2017
20
Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy. ( 26780868 )
2017
21
Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer. ( 27278788 )
2017
22
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. ( 28011482 )
2017
23
Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies. ( 28296724 )
2017
24
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. ( 28089304 )
2017
25
MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein. ( 27959429 )
2017
26
Inhibition of cell survival and proliferation by nimbolide in human androgen-independent prostate cancer (PC-3) cells: involvement of the PI3K/Akt pathway. ( 28025797 )
2017
27
Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells. ( 28351335 )
2017
28
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). ( 28532400 )
2017
29
Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility. ( 28373430 )
2017
30
Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/I^-catenin signaling. ( 28098905 )
2017
31
Synthesis and evaluation of [(64)Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. ( 28533936 )
2017
32
Reply from Authors re: Jens Uwe Stolzenburg, Iason Kyriazis, Evangelos Liatsikos. Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach. Eur Urol 2017;71:159-60: Which Lymphatic Vessels Have To Be Secured During Pelvic Lymph Node Dissection for Prostate Cancer? ( 27666998 )
2017
33
Androgen Mediated Regulation of Endoplasmic Reticulum-Associated Degradation and its Effects on Prostate Cancer. ( 28091582 )
2017
34
EAF2 regulates DNA repair through Ku70/Ku80 in the prostate. ( 27721405 )
2017
35
miRNA-154-5p Inhibits Proliferation, Migration and Invasion by Targeting E2F5 in Prostate Cancer Cell Lines. ( 27074041 )
2017
36
Serotonin receptor 4 (5-hydroxytryptamine receptor Type 4) regulates expression of estrogen receptor beta and cell migration in hormone-naive prostate cancer. ( 28195088 )
2017
37
mTUEPA: Trans-Urethral Monopolar Enucleation of Prostatic Adenoma. Preliminary Report. ( 28087281 )
2017
38
Xanthogranulomatous Prostatitis, a Rare Prostatic Entity. ( 27800297 )
2017
39
Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer. ( 28091918 )
2017
40
miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. ( 28384067 )
2017
41
RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells. ( 28257035 )
2017
42
Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclinA D1 and MMP-7. ( 27922675 )
2017
43
Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions. ( 27931798 )
2017
44
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. ( 27358489 )
2017
45
Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. ( 28533399 )
2017
46
Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men. ( 28353585 )
2017
47
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
48
Huge Prostatic Utricle with Transitional Cell Carcinoma in an Adult. ( 28065811 )
2017
49
Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by Hsa-miR-125A-3P via Modulation of MTA1 Signaling. ( 28088556 )
2017
50
Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. ( 27983526 )
2017

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 CXCL8 IL10 IL1B IL6 TGFB1 TNF
2
Show member pathways
13.3 CXCL8 IL10 IL1B IL6 TGFB1 TNF
3
Show member pathways
13.24 CXCL8 IL10 IL1B IL6 TGFB1 TNF
4
Show member pathways
12.9 CXCL8 IL10 IL1B IL6 TGFB1 TNF
5
Show member pathways
12.85 CXCL8 IL10 IL1B IL6 TGFB1 TNF
6 12.66 CXCL8 IL6 KLK3 NKX3-1 TGFB1
7
Show member pathways
12.64 IL1B IL6 TGFB1 TNF
8
Show member pathways
12.59 IL10 IL1B IL6 TGFB1 TNF
9
Show member pathways
12.54 IL10 IL1B IL6 TNF
10
Show member pathways
12.44 IL10 IL1B IL6 TGFB1 TNF
11
Show member pathways
12.32 CXCL8 IL1B IL6 TNF
12
Show member pathways
12.26 CXCL8 IL1B IL6 TNF
13
Show member pathways
12.25 IL10 IL1B TGFB1 TNF
14
Show member pathways
12.18 CXCL8 IL1B IL6 TNF
15
Show member pathways
12.17 CXCL8 IL10 IL1B IL6 TNF
16 12.16 IL10 IL1B IL6 TGFB1 TNF VDR
17 12.09 CXCL8 IL10 IL1B IL6 NKX3-1 TNF
18
Show member pathways
12.04 IL10 IL6 TGFB1
19 12.03 CXCL8 IL1B IL6 TGFB1 TNF
20 12.01 IL6 TGFB1 TNF
21 12 IL1B TGFB1 TNF
22 11.96 CXCL8 IL1B IL6 TGFB1
23 11.95 IL10 IL6 TNF
24
Show member pathways
11.95 IL10 IL1B IL6 TGFB1 TNF
25 11.91 IL1B IL6 TNF
26 11.9 CXCL8 IL1B IL6 TGFB1 TNF
27
Show member pathways
11.89 IL1B IL6 TGFB1
28 11.86 IL1B IL6 TNF
29 11.85 CXCL8 IL1B TNF
30 11.85 CXCL8 IL1B IL6 TGFB1 TNF
31
Show member pathways
11.84 CXCL8 IL6 TGFB1
32 11.8 CXCL8 IL1B IL6
33 11.79 CXCL8 IL10 IL1B IL6 TGFB1 TNF
34 11.77 IL10 IL1B TNF
35 11.76 IL10 IL1B IL6 TGFB1 TNF
36 11.75 IL10 IL6 TGFB1 TNF
37 11.74 CXCL8 IL10 IL1B IL6 TNF
38
Show member pathways
11.69 CXCL8 IL1B IL6 TNF
39 11.63 CXCL8 IL1B IL6 TNF
40 11.62 CXCL8 IL10 IL1B IL6 TGFB1 TNF
41 11.57 CXCL8 IL6 TGFB1
42 11.57 CXCL8 IL1B IL6 TGFB1 TNF
43 11.53 IL1B TGFB1 TNF
44 11.53 IL1B KLK3 TNF
45 11.53 IL1B IL6 TNF VDR
46
Show member pathways
11.44 IL10 TGFB1 TNF
47 11.41 CXCL8 IL10 IL1B IL6 TNF
48 11.39 IL10 IL1B IL6 TNF
49 11.38 IL10 IL1B IL6 TNF
50 11.33 IL1B IL6 TNF

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CXCL8 IL10 IL1B IL6 KLK3 MSMB
2 extracellular space GO:0005615 9.28 CXCL8 IL10 IL1B IL6 KLK3 MSMB

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.99 ADRA1A IL10 IL6 TGFB1
2 leukocyte migration GO:0050900 9.95 IL1B PROS1 TGFB1 TNF
3 positive regulation of transcription, DNA-templated GO:0045893 9.95 IL10 IL1B IL6 NKX3-1 TGFB1 TNF
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 ADRA1A IL6 TGFB1 TNF
5 aging GO:0007568 9.92 ADRA1A IL10 IL6 TGFB1
6 cellular response to tumor necrosis factor GO:0071356 9.87 CXCL8 IL6 NKX3-1
7 positive regulation of protein phosphorylation GO:0001934 9.87 IL1B NKX3-1 TGFB1 TNF
8 response to organic substance GO:0010033 9.86 IL10 TGFB1 TNF
9 positive regulation of protein kinase B signaling GO:0051897 9.85 IL6 TGFB1 TNF
10 cellular response to interleukin-1 GO:0071347 9.85 CXCL8 IL6 NKX3-1
11 cellular response to organic cyclic compound GO:0071407 9.85 IL1B TGFB1 TNF
12 inflammatory response GO:0006954 9.85 CXCL8 IL10 IL1B IL6 TGFB1 TNF
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 IL6 TGFB1 TNF
14 response to glucocorticoid GO:0051384 9.83 IL10 IL6 TNF
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 IL1B IL6 TGFB1 TNF
16 positive regulation of MAP kinase activity GO:0043406 9.81 PDE5A TGFB1 TNF
17 cell growth GO:0016049 9.81 ADRA1A IL6 TGFB1
18 cellular response to lipopolysaccharide GO:0071222 9.8 CXCL8 IL10 IL6 TNF
19 positive regulation of gene expression GO:0010628 9.8 IL1B IL6 NKX3-1 TGFB1 TNF VDR
20 positive regulation of cell division GO:0051781 9.79 IL1B NKX3-1 TGFB1
21 negative regulation of fat cell differentiation GO:0045599 9.77 IL6 TGFB1 TNF
22 positive regulation of interleukin-6 production GO:0032755 9.76 IL1B IL6 TNF
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.75 IL1B IL6 TNF
24 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.73 IL10 IL1B IL6 TNF
25 positive regulation of NF-kappaB import into nucleus GO:0042346 9.72 IL1B TNF
26 negative regulation of myoblast differentiation GO:0045662 9.72 TGFB1 TNF
27 defense response to protozoan GO:0042832 9.72 IL10 IL6
28 positive regulation of histone acetylation GO:0035066 9.71 IL1B TGFB1
29 embryonic digestive tract development GO:0048566 9.71 CXCL8 TNF
30 negative regulation of lipid catabolic process GO:0050995 9.71 IL1B TNF
31 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 IL10 TNF
32 positive regulation of chemokine production GO:0032722 9.71 IL6 TNF
33 negative regulation of T cell proliferation GO:0042130 9.71 IL10 PDE5A TGFB1
34 negative regulation of growth of symbiont in host GO:0044130 9.7 IL10 TNF
35 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 IL1B TNF
36 cellular response to hepatocyte growth factor stimulus GO:0035729 9.7 IL10 IL6
37 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.69 IL1B TNF
38 response to molecule of bacterial origin GO:0002237 9.69 CXCL8 IL10
39 lipopolysaccharide-mediated signaling pathway GO:0031663 9.69 IL1B TGFB1 TNF
40 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL1B TNF
41 negative regulation of lipid storage GO:0010888 9.68 IL6 TNF
42 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
43 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
45 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
46 sequestering of triglyceride GO:0030730 9.61 IL1B TNF
47 positive regulation of mononuclear cell migration GO:0071677 9.6 TGFB1 TNF
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL10 IL1B TNF
49 receptor biosynthetic process GO:0032800 9.56 IL10 TNF
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 IL1B TNF

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CXCL8 IL10 IL1B IL6 TGFB1 TNF

Sources for Prostatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....